Skip to main content
U.S. flag

An official website of the United States government

Return to Search

New COVID-19 Treatments Add-On Payment (NCTAP)

Instructions for Coding for NCTAP

Final

Issued by: Centers for Medicare & Medicaid Services (CMS)

CMS issued an Interim Final Rule with Comment Period that established the New COVID-19 Treatments Add-on Payment (NCTAP) under the Medicare Inpatient Prospective Payment System (IPPS). The NCTAP, designed to mitigate potential financial disincentives for hospitals to provide new COVID-19 treatments, is effective from November 2, 2020, until the end of the COVID-19 public health emergency (PHE).

Through the NCTAP, the Medicare Program will provide an enhanced payment for eligible inpatient cases that use certain new products with current FDA approval or emergency use authorization (EUA) to treat COVID-19, including the following:

  • On August 23, 2020, the FDA issued (reissued on November 30, 2020, and revised on March 9, 2021) an EUA for the use of COVID-19 convalescent plasma for treating COVID-19 in hospitalized patients
  • On October 22, 2020, the FDA approved remdesivir (Veklury) for the treatment of COVID-19 for adults and certain pediatric patients requiring hospitalization
  • On November 19, 2020, the FDA issued (and amended on December 20, 2021) an EUA for the use of baricitinib (Olumiant) for the treatment of suspected or laboratory confirmed COVID-19 in certain hospitalized patients
  • On December 22, 2021, the FDA issued an EUA for molnupiravir for the treatment of mild-to-moderate COVID-19 in certain adults who are at high-risk for progression to severe COVID-19, including hospitalization or death.
  • On December 23, 2021, the FDA issued an EUA for nirmatrelvir (Paxlovid) for the treatment of mild-to-moderate COVID-19 in certain adults and pediatric patients at high risk for progression to severe COVID-19, including hospitalization or death. 
     

For eligible cases, the NCTAP is equal to the lesser of these:

Coding for NCTAP

NCTAP claims are those that are eligible for the 20% add-on payment under Section 3710 of the CARES Act. Eligible claims have an ICD-10-CM diagnosis code U07.1 (COVID-19) and one of the following:

  • ICD-10-PCS codes for remdesivir (Veklury), COVID-19 convalescent plasma, or baricitinib (Olumiant).
  • National Drug Codes (NDC) for nirmatrelvir and molnupiravir

Codes for Remdesivir or COVID-19 Convalescent Plasma for Hospital Discharges on or after November 2, 2020

ICD-10-PCS CodeDescription
XW033E5Introduction of remdesivir anti-infective into peripheral vein, percutaneous approach, new technology group 5
XW043E5Introduction of remdesivir anti-infective into central vein, percutaneous approach, new technology group 5
XW13325Transfusion of convalescent plasma (nonautologous) into peripheral vein, percutaneous approach, new technology group 5
XW14325Transfusion of convalescent plasma (nonautologous) into central vein, percutaneous approach, new technology group 5

 

Codes for Baricitinib for Hospital Discharges between November 19, 2020 and December 31, 2020

ICD-10-PCS CodeDescription
XW0DXF5Introduction of other new technology therapeutic substance into mouth and pharynx, external approach, new technology group 5
3E0G7GCIntroduction of other therapeutic substance into upper G.I. via natural or artificial opening
3E0H7GCIntroduction of other therapeutic substance into lower G.I. via natural or artificial opening

 

Codes for Baricitinib for Hospital Discharges on or after January 01, 2021 through the End of the COVID-19 PHE

ICD-10-PCS CodeDescription
XW0DXM6Introduction of baricitinib into mouth and pharynx, external approach, new technology group 6
XW0G7M6Introduction of baricitinib into upper GI, via natural or artificial opening, new technology group 6
XW0H7M6Introduction of baricitinib into lower GI, via natural or artificial opening, new technology group 6

 

Codes for nirmatrelvir (PAXLOVID™) for Hospital Discharges on or after December 23, 2021

National Drug Code

Description

00069108506

nirmatrelvir (Paxlovid)

00069108530

nirmatrelvir (Paxlovid)

NDCs are listed as 11-digit codes for hospital institutional billing


Codes for molnupiravir for Hospital Discharges on or after December 22, 2021

National Drug Code

Description

00006505506

molnupiravir

00006505507

molnupiravir

NDCs are listed as 11-digit codes for hospital institutional billing

Hospitals should report the ICD-10-PCS code(s) or NDC(s) for all products administered during the stay, even if the hospital got the product for free. Hospitals shouldn’t report charges for products they got for free.
 
Note:
A hospital shouldn't seek additional payment on the claim for drugs or biologicals to treat patients with known or suspected COVID-19 that the government purchased or provided for free. See the CMS Medicare Claims Processing Manual, Pub. 100-04, Chapter 32, Section 67 (PDF).

 

For more information on COVID-19 diagnosis and procedure codes, visit the “Latest News” section of the MS-DRG Classifications and Software webpage.

You can also review our COVID-19 FAQs (PDF), which include information on NCTAP and our implementation of Section 3710 of the CARES Act.

HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.

DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.